InvestorsHub Logo
Followers 5
Posts 528
Boards Moderated 0
Alias Born 07/16/2013

Re: oakrock post# 89572

Sunday, 01/06/2019 12:54:08 PM

Sunday, January 06, 2019 12:54:08 PM

Post# of 108191
Thanks for sharing; I was not aware of this:

“The assessment of the TNFa and IFN-? response based on data from eight of the anticipated nine patients to be enrolled in stage 1 confirmed that the clinical study has already met the target for the overall rate of vaccine-induced T-cell response, paving the way for us to progress to stage 2,” said the study’s lead investigator Andrew G. Sikora, MD, PhD, of the Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery at Baylor College of Medicine. “


https://ir.advaxis.com/press-release/clinical-data-updates/advaxis-announces-phase-2-head-and-neck-cancer-study-axal

I am not a trained financial professional, and all posts are my bar stool amateur opinion.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News